Regenicin Inc (RGIN)

[mdub]

FDA orphan drug approval is given to products that are targeted at diseases that affect a very small proportion of the population, and thus will have relatively small financial return. The designation gives the company 7 years of exclusive sales which is about twice what most drugs end up with following final FDA approval. It does not mean the product can be used for anything other than research/trials as of now. That requires further approval from the FDA.